Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tobramycin 80mg/2ml solution for injection vials
0501040U0AAACAC
|
Tobramycin (Systemic) | Tobramycin | Infections | 109 |
|
Tobramycin 300mg/5ml nebuliser liquid ampoules
0501040U0AAAGAG
|
Tobramycin (Systemic) | Tobramycin | Infections | 81 |
|
Tobramycin 300mg/4ml nebuliser liquid ampoules
0501040U0AAAKAK
|
Tobramycin (Systemic) | Tobramycin | Infections | 32 |
|
Tobramycin 40mg/1ml solution for injection vials
0501040U0AAABAB
|
Tobramycin (Systemic) | Tobramycin | Infections | 4 |
|
Tobramycin 28mg inhalation powder capsules with device
0501040U0AAALAL
|
Tobramycin (Systemic) | Tobramycin | Infections | 3 |
|
Tobramycin 40mg/5ml oral solution
0501040U0AAAHAH
|
Tobramycin (Systemic) | Tobramycin | Infections | 2 |
|
Tobramycin 170mg/1.7ml nebuliser liquid ampoules
0501040U0AAANAN
|
Tobramycin (Systemic) | Tobramycin | Infections | No data available |
|
Tobramycin 20mg/2ml solution for injection vials
0501040U0AAAAAA
|
Tobramycin (Systemic) | Tobramycin | Infections | No data available |
|
Tobramycin 20mg/5ml oral solution
0501040U0AAAMAM
|
Tobramycin (Systemic) | Tobramycin | Infections | No data available |
|
Tobramycin 240mg/6ml solution for injection vials
0501040U0AAAIAI
|
Tobramycin (Systemic) | Tobramycin | Infections | No data available |
|
Tobramycin 40mg/1ml solution for injection ampoules
0501040U0AAAEAE
|
Tobramycin (Systemic) | Tobramycin | Infections | No data available |
|
Tobramycin 80mg/2ml solution for infusion ampoules
0501040U0AAAFAF
|
Tobramycin (Systemic) | Tobramycin | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.